Thalassemia intermedia is associated with a proatherogenic biochemical phenotype

Blood Cells, Molecules, and Diseases

Volumn 46, Issue 4, 2011, Pages 294-299

  Lai, Maria Eliana ^a   Vacquer, Stefania ^a   Carta, Maria Paola ^a   Spiga, Alessandra ^a   Cocco, Pierluigi ^a   Angius, Fabrizio ^a   Mandas, Antonella ^a   Dessì, Sandra ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Arteriosclerosis; Cholesterol metabolism; Iron metabolism; Thalassemias

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTERASE; HEPCIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1ALPHA; IRON; MESSENGER RNA; TRANSFERRIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOPLASM; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IRON BALANCE; IRON BLOOD LEVEL; IRON METABOLISM; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; TRANSFERRIN BLOOD LEVEL;

ADULT; ARTERIOSCLEROSIS; BETA-THALASSEMIA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; IRON; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 79953720556     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.02.004     Document Type: Article

References (30)

1. Rund D., Rachmilewitz E. Beta-thalassemia. N. Engl. J. Med. 2005, 353:1135-1146.
2. Camaschella C., Cappellini M.D. Thalassemia intermedia. Haematologica 1995, 801:58-68.
3. Aessopos A., Farmakis D., Karagiorga M., et al. Cardiac involvement in thalassemia intermedia: a multi-center study. Blood 2001, 97:3411-3416.
4. Aessopos A., Kati M., Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007, 92:658-665.
5. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
6. Taher A., Isma'eel H., Cappellini M.D. Thalassemia intermedia: revisited. Blood Cells Mol. Dis. 2006, 37:12-20.
7. Origa R., Barella S., Argiolas G.M., et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica 2008, 93:1095-1096.
8. Aessopos A., Tsironi M., Andreopoulos A., Farmakis D. Heart disease in thalassemia intermedia. Hemoglobin 2009, 33:170-176.
9. Auer J.W., Berent R., Weber T., Eber B. Iron metabolism and development of atherosclerosis. Circulation 2002, 106:7.
10. Ganz T. Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Prac. Res. Clin. Haematol. 2005, 18:171-182.
11. Camberlein E., Zanninelli G., Détivaud L., et al. Anemia in β-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. Haematologica 2008, 93:111-115.
12. Lee P., Peng H., Gelbart T., Wang L., Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. PNAS 2005, 102:1906-1910.
13. Nasr M., Abdelmaksoud A., Abd El-Aal K., Mabrouk N., Ismael W. Plasma lipid profile and lipid peroxidation in beta-thalassemic children. J. Clin. Lipidol. 2008, 6:405-409.
14. Amendola G., Danise P., Todisco N., et al. Lipid profile in beta-thalassemia intermedia patients: correlation with erythroid bone marrow activity. Int. J. Lab. Hematol. 2007, 29:172-176.
15. Tiwari R.L., Singh V., Barthwal M.K. Macrophages: an elusive yet emerging therapeutic target of atherosclerosis. Med. Res. Rev. 2008, 28:483-544.
16. Rosatelli M.C., Dozy A., Faà V., et al. Molecular characterization of beta-thalassemia in the Sardinian population. Am. J. Hum. Genet. 1992, 50:422-426.
17. Wilson P.W., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8:737-741.
18. Goldbourt U., Yaari S., Medalie J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler. Thromb. Vasc. Biol. 1997, 17:107-113.
19. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
20. Olivieri N.F. The β-thalassemias. N. Engl. J. Med. 1999, 341:99-108.
21. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89:739-761.
22. Zhang W.J., Frei B. Intracellular metal ion chelators inhibit TNF? induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. Free Radic. Biol. Med. 2003, 34:674-682.
23. Koo S.W., Casper K.A., Otto K.B., Gira A.K., Swerlick R.A. Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J. Invest. Dermatol. 2003, 120:871-879.
24. Nishiyama T., Hanaoka K. Free hemoglobin concentrations in patients receiving massive blood transfusion during emergency surgery for trauma. Can. J. Anesth. 2000, 47:881-885.
25. Taher A., Abou-Mourad Y., Abchee A., et al. Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?. Hemoglobin 2002, 26:107-112.
26. Taher A.T., Otrock Z.K., Uthman I., et al. Thalassemia and hypercoagulability. Blood Rev. 2008, 22:283-292.
27. Taher A.T., Musallam K.M., Karimi M., et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010, 115:1886-1892.
28. Calandra S., Bertolini S., Pes G.M., et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Semin. Vasc. Med. 2004, 4:271-278.
29. Namazi M. Minor thalassemia as a protective factor against cerebrovascular accidents. Med. Hypotheses 2002, 59:361-362.
30. Shalev H., Kapelushnik J., Moser A., et al. Hypocholesterolemia in chronic anemias with increased erythropoietic activity. Am. J. Hematol. 2006, 82:199-202.